Striving for optimal bronchodilation: focus on olodaterol

References

• PrigalSJFuchsAMSchulmanPMThe treatment of asthma with rectal suppositories of aminophylline and sodium pentobarbitalJ Allergy19461717217721027126
   PubMedGoogle Scholar
• JackDAn introduction to salbutamol and other modern β-adrenoreceptors stimulantsPostgrad Med J197147Suppl8114396721
   PubMedGoogle Scholar
• JohnssonGSvedmyrNThiringerGEffect of intravenous propranolol and metoprolol and their interaction on pulmonary function, heart rate and blood pressure in asthmaticsEur J Clin Pharmacol1975841751801233216
   PubMed Web of Science ®Google Scholar
• MinetteAVentilatory results and side-effects of salbutamol given by different routes in coalminers with reversible broncho-obstructionPostgrad Med J197147Suppl55614929394
   PubMedGoogle Scholar
• UllmanASvedmyrNSalmeterol, a new long acting inhaled β2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patientsThorax19884396746782904183
   PubMed Web of Science ®Google Scholar
• BeckerABSimonsFEFormoterol, a new long-acting β2-adrenergic receptors agonist: double-blind comparison with salbutamol and placebo in children with asthmaJ Allergy Clin Immunol19898468918952574732
   PubMed Web of Science ®Google Scholar
• LöfdahlCGChungKFLong-acting β2-adrenoceptor agonists: a new perspective in the treatment of asthmaEur Respir J1991422182261675178
   PubMed Web of Science ®Google Scholar
• CazzolaMSpinaDMateraMGThe use of bronchodilators in stable chronic obstructive pulmonary diseasePulm Pharmacol Ther19971031291449514624
   PubMed Web of Science ®Google Scholar
• SantusPRadovanocicDPaggiaroPWhy use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterolEur J Intern Med201526637938426049917
   PubMed Web of Science ®Google Scholar
• BeierJChanezPMartinotJBSafety, tolerability and efficacy of indacaterol, a novel once-daily β(2)-agonist, in patients with COPD: a 28-day randomised, placebo-controlled clinical trialPulm Pharmacol Ther200720674074917088091
   PubMed Web of Science ®Google Scholar
• VogelmeierCMagnussenHLaForceCOwenRKramerBProfiling the bronchodilator effect of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary diseaseTher Adv Respir Dis20115534535721719531
   PubMedGoogle Scholar
• RidoloEMontagniMOlivieriERole of indacaterol and the newer very long acting β2-agonists in patients with stable COPD: a reviewInt J Chron Obstruct Pulmon Dis2013742543224082783
   PubMed Web of Science ®Google Scholar
• SlackRJBarretVJMorrisonVSIn vitro pharmacological characterization of vilanterol, a novel long-acting-adrenoceptor agonist with 24-hour duration of actionJ Pharmacol Exp Ther2013344121823023131596
   PubMed Web of Science ®Google Scholar
• GibbAYangLPOlodaterol: first global approvalDrugs201373161841184624158691
   PubMed Web of Science ®Google Scholar
• O’ByrnePMBleeckerERBatemanEDOnce-daily fluticasone furoate alone or combined with vilanterol in persistent asthmaEur Respir J201243377378224136330
   PubMed Web of Science ®Google Scholar
• BlairHADeeksEDUmeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary diseaseDrugs2015751617425398674
   PubMed Web of Science ®Google Scholar
• SpinaDCurrent and novel bronchodilators in respiratory diseaseCurr Opin Pulm Med2014201738624247039
   PubMed Web of Science ®Google Scholar
• KeatingGMTiotropium Respimat® Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary diseaseDrugs201474151801181625300412
   PubMed Web of Science ®Google Scholar
• BouyssouTCasarosaPNalineEPharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical modelsJ Pharmacol Exp Ther20103341536220371707
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPRoglianiPβ2-agonist therapy in lung diseaseAm J Respir Crit Care Med2013187769069623348973
   PubMed Web of Science ®Google Scholar
• CostaLRothMMiglinoNTiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathwayPulm Pharmacol Ther2014271293724269928
   PubMed Web of Science ®Google Scholar
• DalbyLSpallekMVoshaarTA review of the development of Respimat® Soft Mist™ InhalerInt J Pharm200428311915363496
   PubMed Web of Science ®Google Scholar
• HochrainerDHolzHKreherCComparison of the aerosol velocity and spray duration of Respimat® Soft Mist™ inhaler and pressurized metered dose inhalersJ Aerosol Med200518327328216181002
   PubMedGoogle Scholar
• PitcairnGReaderSPaviaDDeposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ inhaler compared with deposition by metered dose inhaler or by Turbuhaler® dry powder inhalerJ Aerosol Med200518326427216181001
   PubMedGoogle Scholar
• BatemanESinghDSmithDEfficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studiesInt J Chron Obstruct Pulmon Dis2010519720820714373
   PubMedGoogle Scholar
• van NoordJASmeetsJJDrenthBM24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPDPulm Pharmacol Ther201124666667221839850
   PubMed Web of Science ®Google Scholar
• FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
   PubMed Web of Science ®Google Scholar
• ZuWallackRAllenLHernandezGEfficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J Chron Obstruct Pulmon Dis201491133114425342898
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• FergusonGTFležarMKornSEfficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysisAdv Ther201532652353626112656
   PubMed Web of Science ®Google Scholar
• McGarveyLNiewoehnerDMagderSOne-year safety of olodaterol once daily via Respimat® in patients with GOLD 2–4 chronic obstructive pulmonary disease: results of a pre-specified pooled analysisCOPD201512548449325692310
   PubMedGoogle Scholar
• JoosGFAumannJLCoeckCA randomised, double-blind, four-way, crossover trial comparing the 24-hours FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary diseaseRespir Med2015109560661525776199
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. [homepage on Internet] Available from: www.ginasthma.orgAccessed August 13, 2015
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. [homepage on Internet] Available from: www.goldcopd.orgAccessed August 13, 2015
   Google Scholar
• FesticEScanlonPDIncident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?Am J Respir Crit Care Med201519114114825409118
   PubMed Web of Science ®Google Scholar
• SpinaDCurrent and novel bronchodilators in respiratory diseaseCurr Opin Pulm Med2014201738624247039
   PubMed Web of Science ®Google Scholar
• MontuschiPCiabattoniGBronchodilating drugs for chronic obstructive pulmonary disease: current status and future perspectiveJ Med Chem201558104131416425587755
   PubMed Web of Science ®Google Scholar
• MateraMGRoglianiPCazzolaMQVA149 (indacaterol/glycopirronium) for the treatment of chronic obstructive pulmonary diseaseExpert Opin Pharmacother20151671079109025843089
   PubMed Web of Science ®Google Scholar
• RidoloEMontagniMRiario-SforzaGGCombination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safetyTher Adv Respir Dis201592495525691493
   PubMed Web of Science ®Google Scholar
• BabuKSMorjariaJBClinico-pharmacological profile of the fixed dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary diseaseTher Adv Respir Dis201592566825754881
   PubMed Web of Science ®Google Scholar
• van BovenJFStuurman-BiezeAGHiddinkEGMedication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherenceJ Manag Care Spec Pharm201420878679225062071
   PubMed Web of Science ®Google Scholar
• RoskellNSAnzuetoAHamiltonOnce-daily long-acting β-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterolInt J Chron Obstruct Pulmon Dis2014981382425114521
   PubMed Web of Science ®Google Scholar
• CazzolaMBeehKMPriceDAssessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPDPulm Pharmacol Ther201531687825727846
   PubMed Web of Science ®Google Scholar